Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNA: Ultevursen in Retinitis Pigmentosa Due to USH2A Exon 13 Mutations
NCT06627179Phase 2Active, not recruiting
- Sponsor
- Laboratoires Théa
- Start
- Dec 2024
- Primary completion
- Jul 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of ultevursen in retinitis pigmentosa (RP) (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Efficacy after 24 months of treatment. Started Dec 2024; status: active, not recruiting.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT06627179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627179.